Inventor
LUI REBECCA M
US40 patents
Patents
40 patentsUS9169261B2Oct 27, 2015
CXCR7 antagonists
CHEMOCENTRYX INC13 citations92
US10562896B2Feb 18, 2020
6-5 fused rings as C5a inhibitors
CHEMOCENTRYX INC11 citations86
US11713307B2Aug 1, 2023
Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases
CHEMOCENTRYX INC8 citations85
US11384079B2Jul 12, 2022
6-5 fused rings as C5a inhibitors
CHEMOCENTRYX INC5 citations84
US10759807B2Sep 1, 2020
Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors
CHEMOCENTRYX INC7 citations84
US10683294B2Jun 16, 2020
5-5 fused rings as C5a inhibitors
CHEMOCENTRYX INC8 citations84
US10532982B2Jan 14, 2020
Processes and intermediates in the preparation of C5aR antagonists
CHEMOCENTRYX INC4 citations84
US10464934B2Nov 5, 2019
Substituted tetrahydropyrans as CCR2 modulators
CHEMOCENTRYX INC5 citations84
US10266492B2Apr 23, 2019
Processes and intermediates in the preparation of C5aR antagonists
CHEMOCENTRYX INC8 citations84
US9783540B2Oct 10, 2017
Substituted tetrahydropyrans as CCR2 modulators
CHEMOCENTRYX INC7 citations84
US9783544B2Oct 10, 2017
CXCR7 antagonists
CHEMOCENTRYX INC4 citations84
US8916601B2Dec 23, 2014
Aza-aryl 1H-pyrazol-1-YL benzene sulfonamides
CHEMOCENTRYX INC12 citations84
US9340509B2May 17, 2016
CCR6 compounds
CHEMOCENTRYX INC4 citations82
US11485737B2Nov 1, 2022
Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors
CHEMOCENTRYX INC2 citations73
US11479553B2Oct 25, 2022
5-5 fused rings as C5a inhibitors
CHEMOCENTRYX INC3 citations73
US11434230B2Sep 6, 2022
2-oxindole compounds
CHEMOCENTRYX INC1 citations73
US11059825B2Jul 13, 2021
CXCR7 antagonists
CHEMOCENTRYX INC2 citations73
US10759789B2Sep 1, 2020
2-oxindole compounds
CHEMOCENTRYX INC2 citations73
US10596163B2Mar 24, 2020
Aza-aryl 1H-pyrazol-1-yl benzene sulfonamides
CHEMOCENTRYX INC3 citations73
US10421748B2Sep 24, 2019
2-oxindole compounds
CHEMOCENTRYX INC3 citations73
US10287292B2May 14, 2019
CXCR7 antagonists
CHEMOCENTRYX INC1 citations73
US10137120B2Nov 27, 2018
Aza-aryl 1H-pyrazol-1-yl benzene sulfonamides
CHEMOCENTRYX INC2 citations73
US11427541B2Aug 30, 2022
Salt forms of a complement component C5A receptor
CHEMOCENTRYX INC2 citations72
US11026935B2Jun 8, 2021
Free base crystalline form of a complement component C5a receptor
CHEMOCENTRYX INC5 citations72
US9795599B2Oct 24, 2017
CCR6 compounds
CHEMOCENTRYX INC2 citations72
US11807609B2Nov 7, 2023
Deuterated compounds as immunomodulators
CHEMOCENTRYX INC0 citations63
US11773091B2Oct 3, 2023
6-5 fused rings as C5a inhibitors
CHEMOCENTRYX INC0 citations63
US11608336B2Mar 21, 2023
Prodrugs of fused-bicyclic C5aR antagonists
CHEMOCENTRYX INC1 citations63
US12497383B2Dec 16, 2025
Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases
CHEMOCENTRYX INC0 citations62
US12371433B2Jul 29, 2025
Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases
CHEMOCENTRYX INC0 citations62
US12139475B2Nov 12, 2024
2-oxindole compounds
CHEMOCENTRYX INC0 citations62
US12054484B2Aug 6, 2024
Substituted tetrahydropyrans as CCR2 modulators
CHEMOCENTRYX INC0 citations62
US11866429B2Jan 9, 2024
Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases
CHEMOCENTRYX INC0 citations62
US11845729B2Dec 19, 2023
Processes and intermediates in the preparation of C5aR antagonists
CHEMOCENTRYX INC0 citations62
US11834452B2Dec 5, 2023
CXCR7 antagonists
CHEMOCENTRYX INC0 citations62
US10117865B2Nov 6, 2018
CCR6 compounds
CHEMOCENTRYX INC1 citations62
US11603356B2Mar 14, 2023
Amorphous form of a complement component C5a receptor
CHEMOCENTRYX INC1 citations59
US12448373B2Oct 21, 2025
Azetidinyl-acetamides as CXCR7 inhibitors
CHEMOCENTRYX INC0 citations51
US10786494B2Sep 29, 2020
CCR6 compounds
CHEMOCENTRYX INC0 citations51
US12018016B2Jun 25, 2024
Aryl sulfonyl (hydroxy) piperidines as CCR6 inhibitors
CHEMOCENTRYX INC0 citations50